Skip to content

Amplia Therapeutics Ltd. uploaded a Earnings Report
May 30, 2024

Follow Follow

Amplia Therapeutics Annual Report – YE March 31st, 2024

Report Highlights:

  • Amplia Therapeutics is pleased to announce its notable progress made throughout the past year. With the ACCENT trial remaining as the primary focus, trials have achieved a 93% disease control rate in Phase 1b dose-escalation stage for pancreatic cancer, surpassing historical averages of standard chemotherapy.
  • Preclinical studies discovered that narmafotinib enhances the efficacy of the chemotherapy regimen FOLFIRINOX in pancreatic cancer models, seeking patent protection for this combination therapy and collaborating with CSIRO on novel formulations for scar reduction and wound healing.
  • Amplia expanded its international presence by securing regulatory approvals from the Korean Ministry of Food and Drug Safety for the ACCENT trial and the US FDA for an Investigational New Drug application, with the World Health Organization officially recognizing narmafotinib as the International Nonproprietary Name for AMP945.